Deals and Financings
• AkesoBio of Zhongshan filed for a $300 million Hong Kong IPO to develop its portfolio of 18 novel mono- and bi-specific antibodies;
• Shenzhen Lachesis Mhealth raised $21 million in a Series B+ round to support its medical devices for patient care in hospitals;
• Shanghai Junshi Bio invested $1.4 million in Stemirna Therapeutics, a Shanghai company developing mRNA vaccine therapeutics for cancer;
Wuhan Coronavirus Outbreak
• China researchers filed for a China patent to remdesivir, a Gilead candidate aimed at the virus, but pledged not to use the patent if Gilead agrees to supply remdesivir;
• The Gates Foundation will commit up to $100 million to fight 2019-nCoV including support for new vaccines-diagnostics and treatment of patients;
• Gilead Sciences and China authorities, have started a Phase III China trial of remdesivir for the 270 patients suffering from the coronavirus;
• BGI, China's largest sequencing company, opened an emergency coronavirus testing laboratory in Wuhan to examine 10,000 patient samples daily;
Trials and Approvals
• Shanghai's Zai Lab started two China clinical trials of its in-licensed PARP inhibitor, one in gastric cancer and the other in breast cancer;
• Bio-Thera Solutions of Guangzhou reported positive top-line results from a Phase III clinical trial of its Avastin biosimilar.
Stock Symbols: (HK: 1877) (NSDQ: GILD) (NSDQ: ZLAB) (BSE: 500087)
Share this with colleagues: